indicate a dysregulation in T and NK cell systems as well as in B cells. Our research group at the Dept. of Oncology, HUS, were the first to publish a paper on the use of B-cell depletion as therapeutic intervention in CFS [1] . The considerable symptom change in three pilot patients indicates that B-lymphocytes play an important part in symptom maintenance in this chronic, debilitating illness. The study also points to probable mechanisms behind the development of CFS. As a consequence of the pilot study, we are currently, in cooperation with the Dept. of Neurology (HUS), conducting a double-blind, randomized, placebo controlled phase II study on B-lymphocyte depletion using the monoclonal antibody rituximab (Mabthera ®) in patients with CFS (KTS-1-2008, EudraCT 2007-007973-22). The first patient was included in June 2008, and the inclusion phase has been completed (the last patient included in June 2009). The patients are currently being observed for up to 12 months after intervention. The study has now been unblinded to the investigators (mid-February 2010, after the last patient attended the 8 month control visit), while patients remain blinded to treatment allocation until 12 months after intervention.
Interim analysis results confirm that Rituximab is associated with significant clinical response in part of the CFS patient group. Based on clinical assessment, the chief effect parameter is the "overall response" (i.e. response occurring at any time during follow-up). The results (which must for now be treated with confidence) show that 8 out of 15 patients in the rituximab group have experienced a significant response ("overall response"), while 1 out of 15 patients allocated to the placebo group satisfy the criteria for significant response (p=0.017, Fischer's exact test). Moreover, two patients in the rituximab group and one patient in the placebo group have experienced a "moderate" response (in total 10/15 vs 2/15, p=0.009). There is a statistically significant difference in response rate at 7 and 8 months follow-up after intervention, based on the patients' self-reported symptom changes recorded every two weeks. The doctor's symptom registration forms also show a significant difference between the groups at 6 and 8 months control visits (secondary endpoints). The study does not meet its primary endpoint, which is defined the effect on the patients' symptoms after 3 months follow up. There is no difference between the Rituximab and placebo groups with regards to self-reported symptom change or doctor's registration of symptom changes at 3 months compared to baseline. The primary endpoint was defined at a time where we only had knowledge derived from the treatment of two pilot patients. It is worth noting that «improvements» lasting only a few weeks during the first 4-5 months after the intervention also occurred in the placebo group. However, these improvements do not satisfy the response criteria due to the short duration, but affect the statistical analyses until 5 months follow-up. In conclusion, we find a significant difference in favor of the Rituximab group for "overall response" and at the secondary endpoints: symptom change 6 and 8 months after intervention. The patients experiencing significant response noticed a change starting from between 2 and 6 months after intervention. Two patients in the Rituximab group have experienced a major response from approx. 4 months after the intervention, both of whom show no sign of relapse after more than 80 weeks' follow-up. The patients have experienced different response duration (e.g. 2 -6 months, 3 -10 months, 3 -11 months, 6 -8,5 months, 5-7 months) before relapse.
In this study we have not observed any serious toxicity, and there were no hospitalizations or serious infections during follow-up. Two patients, both in the rituximab group, had a transient flare-up of pre-existing psoriasis, which could be a side-effect of the rituximab intervention. The study has provided ample material for research, and biological parameters observed at specific times during follow-up may be correlated to clinical response (or lack of such).
In October 2010 it was claimed that CFS patients were infected with a retrovirus (XMRV) causing their symptoms [2] . The use of B-cell depletion in patients with a persisting viral infection would then be relatively contraindicated. However, three recent articles found no incidence of XMRV in cohorts of CFS patients in England and the Netherlands [3] [4] [5] . Our patients in the pilot series and the randomized study (33 in total) have all been tested for XMRV with multiple PCR assays using both DNA and RNA templates, all of which came out negative.
Two of the patients included in the published pilot study [1] have experienced a documented effect of repeated rituximab infusions. Evaluation of these patients indicates that maintenance treatment can prolong and maintain a major clinical response, with considerable benefit to the patients with regards to quality of life, physical function, participation in work or study, social life and family life.
The hypothesis for KTS-2-2010 is that induction treatment with Rituximab (two infusions with two weeks' interval) followed by maintenance infusions as detailed (up to 15 months) will cause a lasting and considerable response in the patients. Furthermore, the study aims to procure biological material (blood samples) before intervention and throughout follow-up, in extension of the existing biobank. We will use the biobank material in further research into the pathogenesis and possible biomarkers of the illness.
OBJECTIVES AND ENDPOINTS

Primary endpoint:
-to investigate the effect on the symptoms of Chronic Fatigue Syndrome, after two infusions of the monoclonal anti-CD20 antibody Rituximab (Mabthera®) (500 mg/m 2 , max 1000 mg per infusion) given at two weeks' interval, followed by maintenance infusions of Rituximab (500 mg/m 2 , max 1000 mg per infusion) at 3, 6, 10 and 15 months. The primary endpoint "clinical response" is not predefined to any specific time point or interval during follow up, but the response must be recorded as significant on the patient's self-report form (mean fatiguescore ≥ 4,5 for at least 6 consecutive weeks, which must include the registration of mean fatiguescore > 5 at some point). Single response periods and the sum of such periods will be recorded. 
AMENDMENT
Secondary endpoints:
-to investigate the effect on the symptoms of Chronic Fatigue Syndrome, at evaluations 3, 6, 10, 15, 20, 24, 30 and 36 months after start intervention; after two infusions of the monoclonal anti-CD20 antibody Rituximab (Mabthera®) (500 mg/m 2 , max 1000 mg per infusion) given at two weeks' interval, followed by maintenance infusions of Rituximab (500 mg/m 2 , max 1000 mg per infusion) at 3, 6, 10 and 15 months.
-to investigate the duration of the longest consecutive clinical response period (mean fatiguescore ≥ 4,5, including mean fatigue score >5).
-to investigate the fraction of included patients still in response at the end of study (36 months after intervention). The therapeutic effect (for primary and secondary endpoints) is recorded using patient self-report forms and clinical assessment.
-to evaluate toxicity within 36 months of intervention start: two infusions of the monoclonal anti-CD20 antibody Rituximab (Mabthera®) (500 mg/m 2 , max 1000 mg per infusion) given at two weeks' interval, followed by maintenance infusions of Rituximab (500 mg/m 2 , max 1000 mg per infusion) at 3, 6, 10 and 15 months.
-functional MRI of the brain after standardized cognitive stress, before intervention and after 12 months follow-up, in 10 of the included patients; please refer to separate protocol section.
AMENDMENT dated 08.12.11: For patients who have taken part in the KTS-2-2010 or KTS-3-2010 studies and experienced a slow and gradual improvement, but who could not be classed as clinically major responders according to the predefined criteria after 12 months follow-up (including five Rituximab infusions), we wish to intensify the Rituximab treatment during the following year. The aim is to investigate whether these patients can still achieve a clinically major response. We wish to administer up to 6 additional Rituximab infusions (500 mg/m 2 , max 1000 mg) with at least two months intervals, during the following 12 months.
DESIGN
Open phase II study. Single center.
INCLUSION OF PATIENTS
We will include up to 30 evaluable patients with Chronic Fatigue Syndrome (CFS). According to the research protocol for the completed clinical study KTS-1-2008, all 15 patients who were included in KTS-1-2008 and received the placebo intervention will be offered inclusion in this study, if they still meet the inclusion criteria and there are no contraindications to a rituximab intervention.
Patients who have received rituximab treatment in KTS-1-2008 will be offered inclusion no sooner than 12 months after the first treatment. This group will include patients who have experienced a clinical response followed by symptom relapse, and who have been clinically stable during the last 3 months before inclusion in the new study. We also aim to include 2-3 participants from KTS-1-2008 where we believe, based on clinical assessment and patient reports, that the rituximab treatment had some effect on the symptoms, but no clinical response was recorded (late and transient improvement which does not meet the response criteria). Our hypothesis is that these patients may benefit from prolonged B-cell depletion (dose-response effect). Additionally, we will treat two patients from KTS-1-2008 who received rituximab treatment but experienced no clinically relevant response, based on the same assumption that the lack of response may be related in some patients to an insufficient dose and duration of B-cell depletion. We will also include additional patients who have been diagnosed with CFS following a neurological assessment, and who meet the study inclusion criteria. 
INCLUSION CRITERIA
AMENDMENT dated 08.12.11: For patients who have taken part in the KTS-2-2010 or KTS-3-2010 studies and experienced a slow and gradual improvement, but who could not be classed as clinically significant responders according to the predefined criteria after 12 months follow-up (including five Rituximab infusions), we wish to intensify the Rituximab treatment during the following year. The aim is to investigate whether these patients can still achieve a clinically major response. We wish to administer up to 6 additional Rituximab infusions (500 mg/m 2 , max 1000 mg) with at least two months intervals, during the following 12 months.
DATA MANAGEMENT AND STATISTICAL ANALYSIS
The demographic and clinical characteristics of the patient groups will be described. We will focus on longitudinal changes in health-related quality of life. We will record changes for each individual patient and for the patient cohort, with emphasis on changes over time. Statically and clinically significant response will be assessed. The patients will complete a self-report form for symptom change every two weeks throughout the follow up period.
The SF-36 (Short Form 36) questionnaire will also be used for the purpose of patient self-reporting. The questionnaire will be completed by patients before intervention and every 4 months during follow-up. Doctor's assessment of symptoms and toxicity will be performed before treatment and 3, 6, 10, 15, 20, 24, 32 and 36 months after intervention start date, and will be recorded on a separate form.
Due to the lack of diagnostic laboratory tests or other specific tests for this illness, adequate registration will depend on patient symptom variables. Thus the effect variables will relate to the four main symptom categories in CFS: Fatigue, Pain, Cognitive symptoms and Other symptoms (including autonomic symptoms). The patients will also record how they experience the illness as a whole, and the perceived impact of the intervention on their quality of life (refer to patient self-report form). Each patient will also fill inn a registration form (before intervention) scoring his/her present symptoms. Only symptoms which affect the individual patient at baseline according to the registration form (within a main category: Fatigue, Pain, Cognitive, Other) will be analyzed for changes at endpoints. Any symptom change, or lack of such, compared to baseline is recorded by the patients every two weeks during follow-up. A score for each of the main categories is calculated, based on the mean scores for each category of symptom on the form. Longitudinal changes in specific symptoms (within each main category) over time will be analyzed and compared to baseline values for each patient and for the entire cohort. After data analysis at 14 months, 24 months and 36 months we will consider the publication of interim data. We will analyze data for the entire cohort, but also perform separate analyses not including data for the patients with no clinical response in the KTS-1-2008 study, who are nevertheless included in this study (please refer to "Inclusion of patients" above; these patients were included in order to investigate whether treatment dose/maintenance could be relevant to the lack of response in KTS-1-2008). The patients randomized to the placebo arm of KTS-1-2008 have completed a 12 months registration period without receiving any active intervention, and any symptom change after Rituximab infusions will be comparable to the follow-up data after the placebo intervention. Patients who received Rituximab during KTS-1-2008, experiencing response and subsequent relapse, can be compared to their own reports after the KTS-1-2008 intervention (i.e. Rituximab treatment with or without maintenance infusions). We will also record the extent to which the patients are able to participate in educational activities, employment or social life during the study period (36 months). Excel computer software will be used for data input, and SPSS for the purpose of statistical analysis. Data input from questionnaires to Excel will be performed by Øystein Fluge, and monitored/double-checked by Olav Mella. Data monitoring will be performed as and when required. Forms with original data will be stored at the trial sites for 15 years after final report is issued. All computer files will be stored accordingly at the Dept. of Oncology. At each clinical visit, the doctor will dictate an entry in the hospital's electronic medical journal.
INFORMATION VISIT AT THE ONCOLOGY DEPT. OUTPATIENT CLINIC
The patients will attend a consultation at the Dept of Oncology, outpatient clinic for assessment, information and written consent.
EXAMINATION AND REGISTRATION AFTER SIGNED INFORMED CONSENT, BEFORE INCLUSION AND INTERVENTION
Clinical assessment: Assessment of CFS symptomatology and registration of symptom severity on the relevant form. Exclusion of other medical conditions which may cause considerable fatigue such as: hypothyreosis, adrenal insufficiency, malignancy, chronic infections, lung disease, angina pectoris, heart failure, kidney failure, liver disease, other neurological diseases (multiple sclerosis, brain tumors, cerebrovascular disease), endogenous depression or other psychiatric conditions associated with fatigue. 
ADMISSION TO THE ONCOLOGY WARD FOR RITUXIMAB INFUSION
The patients will have completed clinical assessment, inclusion and all relevant tests before being admitted for treatment. The patients will be admitted to the Dept. of Oncology on the morning of treatment. Patients will receive Rituximab 500 mg/m 2 , max. dose 1000 mg, diluted in NaCl 0.9 % to a concentration of 2 mg/ml. The second infusion, at 10-14 days after the first, and maintenance infusions after 3, 6, 10 and 15 months, will all contain the same dose of Rituximab as the first infusion. On the day of treatment all patients will receive the following pre-medication: Cetirizine 10 mg x 1 po, Paracetamol 1 g x 2 po, and Dexamethason 8 mg x 1 po. The intravenous infusion speed will follow the guidelines for Rituximab infusions in lymphoma treatment. A nurse shall be present and monitor blood pressure, heart rate and saturation as specified (see appendix). If the first infusion is administered without any symptoms, the infusions will be given more rapidly, according to guidelines for Rituximab infusions in lymphoma patients (see appendix). If the patient has no sign of clinical response according to medical assessment before the 10 month infusion, the planned maintenance infusions at 10 and 15 months will be cancelled. Patients will continue follow-up at the Dept. of Oncology,outpatient clinic as detailed in the protocol with regards to symptom change and toxicity. At each visit the doctor will perform a clinical assessment and dictate an entry in the patient's electronic records. The patient's completed self-report form (recorded every two weeks) and SF-36 questionnaire for the relevant time period are copied and stored in the patient's case file. Patients who have access to the internet may send scanned anonymized copies the complete self-report forms by e-mail to the study management every 1-2 months, in order to facilitate data registration and input.
SELF-REPORT FORMS FROM PATIENTS
-Each patient will fill in a self-report form for CFS symptoms before treatment (week 0) and thereafter every two weeks for 36 months. Copies of the form are collected at follow-up visits at 0, 3, 6, 10, 15, 20, 24, 30 , and 36 months. The same self-report form has been used in the KTS-1-2008 study, and both doctors and patients expressed that the form recorded longitudinal symptom changes adequately. The SF-36 quality of life questionnaire is used for self-reporting of the patients' symptoms. This form shall be completed every 4 months until 36 months after intervention. SF-36 is a generic form, which has been used frequently during the last 15 years. [7, 8] . A Norwegian, validated version is available [9] . The use of any medications will be recorded. Any side effects, including the occurrence of infections, are recorded.
TOXICITY
Any unexpected serious adverse event which is deadly or life-threatening will be reported to the Regional Ethical Committee (REC) and the Norwegian Medicines Agency (NOMA) within 7 days of the study management being notified of the event.
Other unexpected serious adverse events will be reported within 15 days. Any remaining adverse events will be reported in a combined final report. Only SUSARs will be reported as an individual report. The study management -Head of Dept. Prof Olav Mella and Øystein Fluge, MD, are responsible for reporting SAEs to the REC and NOMA. The safety aspect of the study will be supervised by Prof. Olav Dahl at the Dept. of Oncology, HUS. He will take no part in the clinical evaluation of patients. Work-up before inclusion should exclude patients with suspected immunodeficiency disorders or ongoing active and relevant viral infections. However, the cause of ME/CFS is as yet unknown, and we cannot exclude the possibility that some patients may suffer an ongoing active viral infection, which is undetectable at the work-up, and where B-cell depletion could theoretically cause a clinical deterioration. We have not observed any patients in the pilot series or in the KTS-1-2008 study (in total 33 patients, 18 treated with Rituximab) whom, during up to 2 years' follow-up, have reported a decline in their CFS condition after intervention. Patients will receive information on the safety aspects orally and in the letter of information.
PATIENT WITHDRAWAL DURING STUDY
The patients will be informed verbally and in the written patient information that they may withdraw from the study at any time, without having to state the reason for their decision. The medical reasons for withdrawing a patient from the study may be serious events such as severe allergic reactions during or short time after the infusion. Patients who withdraw from the study due to intercurrent or other diseases or any other reasons, will be followed by their general practitioner according to usual CFS guidelines. If possible, we will attempt to obtain toxicity data from patients who have withdrawn during the study.
BIOLOGICAL SPIN-OFF STUDIES
Our studies show that B-lymphocyte depletion using an anti-CD20 monoclonal antibody (rituximab) may have a therapeutic effect in CFS. We will systematically extend the existing biobank with blood samples from the patients at baseline and throughout 36 months follow-up. The biobank will be a starting point for further research into the pathogenesis of ME/CFS. The mechanisms behind the disease must be charted, and a specific and sensitive biomarker is greatly needed.
In addition to laboratory tests as specified above, blood samples for biobank and research will be collected (following written informed consent) before treatment and at follow-up after 3, 6, 10, 15, 20, 24, 30 and 36 months. We will collect serum, plasma and whole blood at specified time points, as well as blood samples on special tubes for DNA and RNA preservation and protein from lymphocyte fractions. Following written informed consent, some patients may be requested to donate samples of cerebrospinal fluid (frozen after collection) before intervention and possibly after 12 and 24 months follow-up. 
FUNCTIONAL MRI OF THE BRAIN
In collaboration with the senior consultant Gesche Neckelmann (Dept. of Radiology, HUS) and Prof. Kenneth Hugdahl (Institute for Biological and Medical Psychology, UiB) we wish to conduct a substudy using a functional MRI and MR spectroscopy of the brain. The fMRI exam involves a standardized cognitive stress test focusing on memory, and will be performed before intervention and after 12 months follow-up. Ten patients included in either KTS-2-2010 or KTS-3-2011 will be asked to participate in this study. The MRI of the brain does not involve injection of contrast fluid or any other invasive procedure.
FUNDING
The study is investigator initiated and is funded through the research budget at the Dept. of Oncology, HUS. There is no external sponsor for the clinical study. Research originating from the biobank ("Pathogenesis and biomarkers in Chronic Fatigue Syndrome) receives financial support from Western Norway Regional Health Authority for the period 2010-2012.
PUBLICATION
The results -positive or negative -from the clinical study will be published in a reputable medical journal. Co-authorship and order of authors will comply with the Vancouver guidelines.
APPLICATIONS FOR APPROVAL
Applications for approval will be sent to: -The Regional Ethical Committee.
-The Biobank Register (extension of existing biobank). -EudraCT. -The Norwegian Medicines Agency.
